Novo Nordisk A/S (NYSE:NVO) Stock Position Increased by Fox Hill Wealth Management

Fox Hill Wealth Management grew its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 121.3% during the first quarter, HoldingsChannel.com reports. The fund owned 28,320 shares of the company’s stock after buying an additional 15,525 shares during the quarter. Novo Nordisk A/S accounts for about 2.4% of Fox Hill Wealth Management’s portfolio, making the stock its 9th biggest position. Fox Hill Wealth Management’s holdings in Novo Nordisk A/S were worth $3,636,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Cravens & Co Advisors LLC grew its position in Novo Nordisk A/S by 1.0% during the first quarter. Cravens & Co Advisors LLC now owns 8,250 shares of the company’s stock valued at $1,059,000 after buying an additional 85 shares during the period. U.S. Capital Wealth Advisors LLC increased its stake in shares of Novo Nordisk A/S by 0.6% in the 4th quarter. U.S. Capital Wealth Advisors LLC now owns 15,421 shares of the company’s stock worth $1,595,000 after purchasing an additional 90 shares in the last quarter. Clarius Group LLC raised its holdings in Novo Nordisk A/S by 0.5% in the 4th quarter. Clarius Group LLC now owns 18,505 shares of the company’s stock worth $1,914,000 after purchasing an additional 93 shares during the period. Tradewinds Capital Management LLC lifted its position in Novo Nordisk A/S by 2.0% during the fourth quarter. Tradewinds Capital Management LLC now owns 4,955 shares of the company’s stock valued at $513,000 after purchasing an additional 95 shares in the last quarter. Finally, Atlas Brown Inc. grew its holdings in Novo Nordisk A/S by 2.5% during the first quarter. Atlas Brown Inc. now owns 3,823 shares of the company’s stock valued at $491,000 after purchasing an additional 95 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

NVO stock traded down $1.75 during midday trading on Friday, hitting $142.74. The company’s stock had a trading volume of 2,757,544 shares, compared to its average volume of 3,502,773. Novo Nordisk A/S has a 12 month low of $75.56 and a 12 month high of $148.15. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $640.55 billion, a price-to-earnings ratio of 49.22, a price-to-earnings-growth ratio of 1.42 and a beta of 0.41. The company has a 50 day moving average of $135.00 and a two-hundred day moving average of $123.54.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.06. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. The business had revenue of $9.52 billion during the quarter, compared to the consensus estimate of $9.23 billion. On average, analysts expect that Novo Nordisk A/S will post 3.41 EPS for the current year.

Analyst Ratings Changes

NVO has been the topic of several recent research reports. The Goldman Sachs Group started coverage on Novo Nordisk A/S in a research note on Thursday, May 30th. They issued a “buy” rating and a $156.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Monday, June 17th. Argus boosted their price objective on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, June 10th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $163.00 price objective on shares of Novo Nordisk A/S in a research note on Tuesday, June 25th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and a consensus target price of $145.67.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.